check_circleStudy Completed

Hormonal intrauterine contraception

Bayer Identifier:

21279

ClinicalTrials.gov Identifier:

NCT04785950

EudraCT Number:

Not Available

EU CT Number:

Not Available
The aim of this study is to estimate the discontinuation rate of low-dose levonorgestrel-releasing intrauterine system due to self-reported unacceptable menstrual bleeding pattern in Spanish women who are using it for the first time how intrauterine system for long acting contraception

Trial purpose

Researchers are looking for better ways to help women prevent pregnancy. Every month, a woman’s body prepares for pregnancy in a process called the menstrual cycle. When pregnancy does not happen, menstruation occurs. During menstruation, women lose blood and tissue from inside the womb. This bleeding can last for about 2 to 7 days.
Hormonal intrauterine contraception aims to help women prevent pregnancy by stopping the process of the menstrual cycle. Intrauterine means that the contraception is in the form of a device that is inserted into a woman’s womb by her doctor. The device then releases the contraception into the womb.
Researchers have found that when women use hormonal contraception, the disruption to the menstrual cycle can cause changes to how often and for how long women will bleed. So, the researchers in this study want to learn more about the menstrual bleeding patterns of women in Spain who are using hormonal intrauterine contraception for the first time. In other words, In particular for the LNG-IUSs, irregular bleeding due to the local effect of levonorgestrel on the endometrium is common, particularly during the first 3 months of use, and it is of interest to know if this is a major reason why Spanish women discontinue this very effective method and what other factors may be associated with discontinuation. The researchers will then use this information to estimate how many women choose to stop using the contraception. The participants will be able to enroll in this study after requesting hormonal intrauterine contraception from their doctor. They will be women between the ages of 18 and 35 who have never used hormonal intrauterine contraception before.
The participants will visit the study site 3 times. On the first visit, they will receive the hormonal intrauterine contraception. The doctors will also check their health to make sure they can join the study. The participants will visit the study site again 4-12 weeks later, and one last time after 1 year of having the hormonal intrauterine contraception. During these visits, the doctors will ask the participants questions about any medical problems they have and if they want to continue using the contraception. Throughout the study, the participants will use a mobile app to track information about their menstrual bleeding and how they feel about it.

Key Participants Requirements

Sex

Female

Age

18 - 35 Years
  • - Women aged 18 to 35 years.
    - Women who have freely chosen a low-dose LNG-IUS for the first time as contraceptive method and it has been successfully inserted previously to invite the woman to participate in the study.
    - Women capable of reading and writing.
    - Women who signed the informed consent form.
    - Women who are not participating in an investigational program with interventions outside of routine clinical practice.
    - Women without a mental illness and able to make decisions and follow instructions.
    - Women without contraindications to a low-dose LNG-IUS according to the local marketing authorization.
    - Women without concomitant medications that may lead to changes in the bleeding pattern (e.g. antiplatelet and/or anticoagulants).
  • - None

Trial summary

Enrollment Goal
316
Trial Dates
February 2021 - May 2023
Phase
Phase 4
Could I Receive a placebo
No
Products
Unspecified
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Completed
Many locationsMany locations, Spain

Primary Outcome

  • Percentage of women who discontinue the use of low-dose LNG-IUS due to the unacceptability of their menstrual bleeding pattern
    date_rangeTime Frame:
    Up to 12 months

Secondary Outcome

  • Percentage of women who discontinued lowdose LNG-IUS due to other reasons
    date_rangeTime Frame:
    At final visit (up to 12 months)
  • Women’s perception of the amount of information received during preinsertion counselling about the potential changes in menstrual bleeding pattern after lowdose LNG-IUS insertion
    Did you received information during pre-insertion counselling about the potential changes in menstrual bleeding pattern after low-dose LNG-IUS insertion? • A lot • Quite a lot • A moderate amount • Relative little • Very little
    date_rangeTime Frame:
    At final visit (up to 12 months)
  • Potential correlation of women’s perception on pre-insertion counselling with overall satisfaction with menstrual bleeding pattern
    date_rangeTime Frame:
    At final visit (up to 12 months)
  • Usage of the mobile apps to support menstrual tracking (regularly, sporadically, never)
    date_rangeTime Frame:
    At initial visit, follow-up and final visit (up to 12 months)
  • Overall satisfaction with the menstrual app (very satisfied; satisfied; neither satisfied nor dissatisfied; dissatisfied; very dissatisfied)
    date_rangeTime Frame:
    At initial visit, follow-up and final visit (up to 12 months)
  • Correlation between the use of a menstrual app and discontinuation
    date_rangeTime Frame:
    At initial visit, follow-up and final visit (up to 12 months)
  • Correlation between the use of a menstrual app and overall satisfaction with menstrual bleeding pattern
    date_rangeTime Frame:
    At initial visit, follow-up and final visit (up to 12 months)
  • Size of uterine cavity
    date_rangeTime Frame:
    At initial visit (Day 0)
  • Menstrual bleeding pattern with 8 parameters
    8 Parameters: • Presence/absence of menstrual bleeding • Frequency: frequent: <24 days; normal: 24-38 days; infrequent: >38 days • Regularity of withdrawal bleeding: regular, one bleeding episode per cycle; irregular, all those cycles that are not regular • Duration: long: >8 days; normal: 4-8 days; short: <4 days • Quantity: 10 cm visual analogue scale (VAS) (on the left “absence of bleeding”; on the right “worst imaginable bleeding”) • Menstrual pain: 10 cm VAS (on the left “no pain”; on the right “worst imaginable pain” • Presence/absence of intermenstrual vaginal bleeding or spotting: yes; no • Interference in daily activities: not at all; mildly; moderately; severely
    date_rangeTime Frame:
    Up to 12 months
  • Change of menstrual bleeding pattern with 8 parameters between baseline and 4 to12 weeks / final visit
    8 Parameters: • Presence/absence of menstrual bleeding • Frequency: frequent: <24 days; normal: 24-38 days; infrequent: >38 days • Regularity of withdrawal bleeding: regular, one bleeding episode per cycle; irregular, all those cycles that are not regular • Duration: long: >8 days; normal: 4-8 days; short: <4 days • Quantity: 10 cm visual analogue scale (VAS) (on the left “absence of bleeding”; on the right “worst imaginable bleeding”) • Menstrual pain: 10 cm VAS (on the left “no pain”; on the right “worst imaginable pain” • Presence/absence of intermenstrual vaginal bleeding or spotting: yes; no • Interference in daily activities: not at all; mildly; moderately; severely
    date_rangeTime Frame:
    Up to 12 months
  • Correlation between uterine cavity size and menstrual bleeding pattern
    date_rangeTime Frame:
    Up to 12 months
  • Overall satisfaction with menstrual bleeding pattern assessed on a 5-point Likert scale (Very satisfied; Satisfied; Neither satisfied nor dissatisfied; Dissatisfied)
    date_rangeTime Frame:
    At baseline, at the follow-up visit and at the final visit (up to 12 months)
  • Change in satisfaction with menstrual bleeding pattern assessed on a 5-point Likert scale (Very satisfied; Satisfied; Neither satisfied nor dissatisfied; Dissatisfied) between baseline and 4-12 weeks / final visit
    date_rangeTime Frame:
    At baseline, at the follow-up visit and at the final visit (up to 12 months)
  • Correlation between overall satisfaction with menstrual bleeding and the menstrual bleeding pattern
    date_rangeTime Frame:
    At baseline, at the follow-up visit and at the final visit (up to 12 months)
  • Percentage of women that would recommend the use of low-dose LNG-IUS to a friend
    date_rangeTime Frame:
    At final visit (up to 12 months)
  • Days up to discontinuation day
    date_rangeTime Frame:
    at the follow-up visit and at the final visit (up to 12 months)

Trial design

An observational, prospective, multicenter study to assess the continuation rates and user acceptability of bleeding profile in first-time users of low-dose LNG-IUS
Trial Type
Observational
Intervention Type
Drug
Trial Purpose
Other
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A

Additional Information

Click here to find information for studies related to Bayer products. To find this study enter the ClinicalTrials.gov identifier (NCT) number or Bayer Study Identifier (ID) in the search field.